Amundi Nasdaq100 Ucits E... Aktie - ANX

Stärken Sie Ihr Portfolio: Diskussionen in Echtzeit und umsetzbare Handelsideen.

Premium

Current Price

239,30

Gebot

235,10

Fragen

240,00

Volumen

2.711

238,80 Tagesbereich 240,20

0,00 52-Wochen-Bereich 0,00

Handelsende

239,15

Handelsbeginn

240,20

Letzte Trade

239.3

Letzter Handelszeitpunkt

Durchschnittliches Volumen (3 Mio.)

Finanzvolumen

VWAP

ADVENTRX Announces Management Promotions

SAN DIEGO, Feb. 4 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) today announced that, effective immediately, Brian...

ADVENTRX Appoints Icahn Representative to Board of Directors

SAN DIEGO, Feb. 3 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) today announced that Odysseas D. Kostas, M.D. will...

ADVENTRX Pharmaceuticals to Present at the 12th Annual BIO CEO & Investor Conference on February 9

SAN DIEGO, Feb. 2 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) today announced that the Company's Principal...

ADVENTRX Pharmaceuticals Announces Closing of Financing

SAN DIEGO, Jan. 7 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) announced today that it has completed the previously...

ADVENTRX Pharmaceuticals to Present at the OneMedForum Finance Conference on January 13

SAN DIEGO, Jan. 6 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) today announced that the Company's Principal...

ADVENTRX Pharmaceuticals Announces Financing

SAN DIEGO, Jan. 4 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) announced today that it has signed agreements to...

ADVENTRX Pharmaceuticals Submits ANX-530 New Drug Application

SAN DIEGO, Jan. 4 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) announced today that it has submitted a New Drug...

ADVENTRX Pharmaceuticals to Present at the Lippert/Heilshorn Life Sciences Virtual Conference

SAN DIEGO, Dec. 9 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) today announced that the Company's Principal...

ADVENTRX Pharmaceuticals Reports Additional Pre-Clinical Data for ANX-514

South Korean Partner Demonstrates Bioequivalence and Similar Toxicity Profile to Taxotere SAN DIEGO, Dec. 1 /PRNewswire-FirstCall/ -- ADVENTRX...

ADVENTRX Pharmaceuticals Reports Third Quarter Financial Results

SAN DIEGO, Nov. 10 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) today reported financial results for the three and...

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	0	0	0	0	0	0	0	SP
4	0	0	0	0	0	0	0	SP
12	0	0	0	0	0	0	0	SP
26	0	0	0	0	0	0	0	SP
52	0	0	0	0	0	0	0	SP
156	0	0	0	0	0	0	0	SP
260	0	0	0	0	0	0	0	SP

Volumen
% Tops
% Flops

Symbol	Preis	Vol.
ESHBEsprit Holdings Ltd	37,935 € (252.800,00%)	352
RN2North Energy ASA	38,30 € (16.408,62%)	1,6k
C6GCosco Shipping Holdings Co Ltd	38,06 € (2.424,71%)	3,44k
CAOConagra Brands Inc	38,18 € (59,85%)	933
E3O1Nexoptic Technology Corp	0,023 € (48,39%)	71,16k
JWG1John Wood Group Plc	0,38 € (-51,68%)	224,36k
NL8Genesis Ai Corp	0,0124 € (-34,04%)	5k
N8TGenerative AI Solutions Corp	0,09 € (-32,84%)	17,31k
OU5AAvalon Advanced Materials Inc	0,0176 € (-31,25%)	1.000
47GAGo Metals Corp	0,0186 € (-26,77%)	1,33k
D7GNel ASA	0,1991 € (0,40%)	3,68M
3CPXiaomi Corporation	5,473 € (4,31%)	2,26M
VODIVodafone Group plc	0,8002 € (-0,99%)	1,78M
PF8European Lithium Limited	0,035 € (7,36%)	1,37M
M11First Graphene Limited	0,0394 € (4,79%)	1,32M

Foren

Foren anzeigen

Keine Diskussionen Gefunden.

Neuen Thread Erstellen

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Amundi Nasdaq100 Ucits Etf Eur (ANX)

Stärken Sie Ihr Portfolio: Diskussionen in Echtzeit und umsetzbare Handelsideen.

Wichtige Statistiken und Details

ANX Neueste Nachrichten

ADVENTRX Announces Management Promotions

ADVENTRX Appoints Icahn Representative to Board of Directors

ADVENTRX Pharmaceuticals to Present at the 12th Annual BIO CEO & Investor Conference on February 9

ADVENTRX Pharmaceuticals Announces Closing of Financing

ADVENTRX Pharmaceuticals to Present at the OneMedForum Finance Conference on January 13

ADVENTRX Pharmaceuticals Announces Financing

ADVENTRX Pharmaceuticals Submits ANX-530 New Drug Application

ADVENTRX Pharmaceuticals to Present at the Lippert/Heilshorn Life Sciences Virtual Conference

ADVENTRX Pharmaceuticals Reports Additional Pre-Clinical Data for ANX-514

ADVENTRX Pharmaceuticals Reports Third Quarter Financial Results

Beweger

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	0	0	0	0	0	0	0	SP
4	0	0	0	0	0	0	0	SP
12	0	0	0	0	0	0	0	SP
26	0	0	0	0	0	0	0	SP
52	0	0	0	0	0	0	0	SP
156	0	0	0	0	0	0	0	SP
260	0	0	0	0	0	0	0	SP

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	0	0	0	0	0	0	0	SP
4	0	0	0	0	0	0	0	SP
12	0	0	0	0	0	0	0	SP
26	0	0	0	0	0	0	0	SP
52	0	0	0	0	0	0	0	SP
156	0	0	0	0	0	0	0	SP
260	0	0	0	0	0	0	0	SP

Trends

Toplisten

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Amundi Nasdaq100 Ucits Etf Eur (ANX) Börsenkurse

Amundi Nasdaq100 Ucits Etf Eur (ANX)

Stärken Sie Ihr Portfolio: Diskussionen in Echtzeit und umsetzbare Handelsideen.

Wichtige Statistiken und Details

ANX Neueste Nachrichten

ADVENTRX Announces Management Promotions

ADVENTRX Appoints Icahn Representative to Board of Directors

ADVENTRX Pharmaceuticals to Present at the 12th Annual BIO CEO & Investor Conference on February 9

ADVENTRX Pharmaceuticals Announces Closing of Financing

ADVENTRX Pharmaceuticals to Present at the OneMedForum Finance Conference on January 13

ADVENTRX Pharmaceuticals Announces Financing

ADVENTRX Pharmaceuticals Submits ANX-530 New Drug Application

ADVENTRX Pharmaceuticals to Present at the Lippert/Heilshorn Life Sciences Virtual Conference

ADVENTRX Pharmaceuticals Reports Additional Pre-Clinical Data for ANX-514

ADVENTRX Pharmaceuticals Reports Third Quarter Financial Results

Beweger

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Werbung entfernen

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	0	0	0	0	0	0	0	SP
4	0	0	0	0	0	0	0	SP
12	0	0	0	0	0	0	0	SP
26	0	0	0	0	0	0	0	SP
52	0	0	0	0	0	0	0	SP
156	0	0	0	0	0	0	0	SP
260	0	0	0	0	0	0	0	SP